Dianthus Therapeutics’ (DNTH) Outperform Rating Reiterated at Wedbush
Wedbush reissued their outperform rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note ...
Dianthus Therapeutics’ (DNTH) Buy Rating Reaffirmed at Guggenheim
Guggenheim reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $84.00 price ...
Pacira BioSciences: Back On An Uptrend After Positive Developments
Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...
The Scottish Farmer21h
Exploring nutritional strategies for managing dairy transition periods
Explore effective feeding strategies for dairy cows during critical transition periods. Learn from experts about DCAD and mineral binders.
Migraine Again on MSN18h
Nasal Sumatriptan: A Better Route Than a Pill or a Poke?
Keep reading to learn how nasal sumatriptan works, who could benefit, and how it compares with other types of sumatriptan.
Becker's Hospital Review23h
The 'sprint' strategy that cut patient infections by up to 67% at Scripps
Learn how Scripps Health improved their hospitals' LeapFrog scores and patient safety through the implementation of sprint teams and a culture of ownership.
Dexerto20h
Destiny 2 Trials of Osiris: Featured map & weapon this week
Destiny 2’s pinnacle PVP activity, Trials of Osiris, returns yet again. If you want to know what this week’s featured map and weapon are, we have all that and more in this breakdown of the ...